Date added: Thursday 19th May 2016
Latest updated: Wednesday 8th February 2017
Elstree, 19 May, 2016 – Bio Products Laboratory Ltd. (“BPL”), a leading plasma biotherapeutics company, today announces that a group controlled by Creat Group Corporation (“Creat”), has signed a definitive agreement to acquire the company for a total cash consideration of £820 million.
BPL, headquartered in Elstree, Hertfordshire, provides lifesaving therapeutics for conditions related to immune deficiencies, bleeding disorders, and critical care. BPL’s plasma division, the largest supplier of US plasma to third parties, provides specialty and source plasma to manufacturers that also produce lifesaving therapies.
Creat, a leading Chinese investment group, will invest £100 million in BPL to expand production capacity of lifesaving therapies, develop new products and access new markets. BPL’s existing management team is staying with the company, which will remain headquartered in the UK. Creat will support management’s ambition to transform BPL into a global life-sciences champion, serving more customers and patients in a greater number of markets around the world. Creat is a long-term strategic investor with a track record of growing businesses and a deep knowledge of the plasma sector.
Currently, BPL is 80% owned by Bain Capital Private Equity and 20% by the UK Department of Health. BPL’s Board of Directors is unanimously supportive of the proposed sale of the company to Creat. Under Bain Capital’s ownership, the company has been transformed from a loss-making business to a profitable one. More than £50 million has been invested in the business, over 750 new jobs have been created, including over 150 at its UK headquarters, and sales have increased by 58%.
John Perkins, CEO of BPL, said:
“I am delighted by our achievements at BPL in recent years. We have transformed BPL into a growth company by investing in people, production capacity, and new products. Ultimately, we have increased supply and introduced new therapies to better serve patients. Creat and the management team share a common set of values and a vision of what BPL can become. Creat is an ideal partner for BPL’s next phase of growth. The entire BPL management team is excited to be working with Creat and is committed to the future of BPL.”
Mr Ng Yuk, CEO of Creat Group Corporation, said:
“We have come to know the management team at BPL well in recent years and have the highest respect for what they have achieved. We believe we can help BPL achieve its growth ambitions through our long-term investment approach and our deep knowledge of this sector. Our additional investment will create new highly skilled jobs in the UK, as well as increase the supply of important plasma biotherapeutic products for the UK and globally, serving the needs of patients who depend on these lifesaving products.”
- ENDS -
About Bio Products Laboratory Ltd.
BPL (www.bpl.co.uk) is a leading manufacturer of plasma-derived protein therapies with global headquarters in Elstree, England, US headquarters for its Therapeutics operation in Durham, NC. The company exports to more than 45 countries worldwide. BPL has over 60 years of experience developing and manufacturing plasma-derived therapies since being established as part of the Lister Institute in 1950, and currently markets a wide range of products including coagulation factors, human immunoglobulins, and albumin. BPL is committed to continued investment in research and development to maintain its key position as a reliable supplier of high-quality products to patients and healthcare providers worldwide.
About Creat Group Corporation
Creat Group Corporation (www.creatgroup.com) is a leading Chinese investment group founded in 1992 that has significant expertise in the plasma industry. It invests in healthcare and pharmaceuticals, manufacturing, energy, finance, natural resources, and real estate. The company is based in Beijing, China, with other offices in Hong Kong and Shanghai.
Ed Gascoigne-Pees / Hazel Stevenson
+44 203 757 4984 / 89
email@example.com / firstname.lastname@example.org
Charis Gresser / David Litterick
+44 (0) 20 7404 5959